An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

PharmacoEconomics

Volumn 9, Issue 5, 1996, Pages 443-454

  Baladi, Jean François ^a,b   Menon, Devidas ^a   Otten, Nicolaas ^a  

^a Can Coord Off Hlth Technol A   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

AGED; ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG FORMULARY; HUMAN; MALE; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SYMPTOM; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 0029971556     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609050-00007     Document Type: Article

References (13)

1. Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995; 155: 477-81
3. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceulicals. 1st ed. Ottawa: CCOHTA, 1994
4. Lowe FC, McDaniel RL, Chmiel JJ, et al. Economic modeling to assess the costs of treatment with finasteride, terazosin and transurethral resection of the prostate for men with symptoms of benign prostatic hyperplasia. Urology 1995; 46 (4): 477-83
5. Naylor CD, Anderson GM, Goel V, editors. Patterns of health care in Ontario. The Institute for Clinical Evaluation Sciences in Ontario practice atlas. Vol. 1. Ottawa: Canadian Medical Association, 1994
6. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guidelines. Agency for Health Care Policy and Research. Rockville (MD): US Department of Health and Human Services, 1994
7. Stoner E, and members of the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43 (3): 284-94
8. Eddy DM, Hasselblad V, Schachter R. Meta-analysis by the confidence profile method: the statistical synthesis of evidence. Boston (MA): Academic Press, 1992
9. Wasson JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332 (2): 75-9
10. Vermeulen LC. Technology assessment: benign prostatic hyperplasia treatments. Oak Brook (IL): University Hospital Consortium, 1995
11. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: health utilities index. PharmacoEconomics 1995; 7: 503-20
12. Barry MJ, Mulley AG, Fowler FJ, et al. Watchful waiting vs. immediate transurethral resection for symptomatic prostatism. JAMA 1988; 259: 3010-7
13. Krahn MD, Mahoney JE, Eckman EH, et al. Screening for prostate cancer: a decision analytic view. JAMA 1994; 272: 773-80